

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-41. (Canceled)

42. (Currently Amended) A method for preventing and/or treating a disease involving β -sheet fibril formation, other than Alzheimer's Disease, in a subject which comprises administering to the subject a binding-inhibiting amount of a compound other than sRAGE ~~comprising a fragment of sRAGE~~, which compound (i) comprises a fragment of sRAGE and (ii) is capable of inhibiting binding of the β -sheet fibril to RAGE, wherein the β -sheet fibril is formed from an amyloid- β peptide selected from the group consisting of A β (1-39), A β (1-40), A β (1-42) and A β (1-40) Dutch variant, so as to thereby prevent and/or treat a disease involving β -sheet fibril formation other than Alzheimer's Disease in the subject.

43. (Canceled)

44. (Canceled)

45. (Previously Presented) The method of claim 42, wherein the fragment of sRAGE comprises the V-domain of sRAGE.

46-54. (Canceled)

Applicants: David Stern, et al.
Serial No.: 10/049,893
Filed: July 22, 2002
Page 3

55. (Previously Presented) The method of claim 42, wherein the β -sheet fibril is amyloid fibril.
56. (Previously Presented) The method of claim 42, wherein the β -sheet fibril is a prion-derived fibril.
57. (Previously Presented) The method of claim 42, wherein the β -sheet fibril comprises a peptide selected from the group consisting of amyloid- β peptide, amylin, amyloid A, prion-derived peptide, transthyretin, cystatin C, and gelsolin.
58. (Canceled)
59. (Previously Presented) The method of claim 42, wherein the subject is a mammal.
60. (Previously Presented) The method of claim 59, wherein the mammal is a human being.
61. (Previously Presented) The method of claim 59, wherein the administration is intralesional, intraperitoneal, intramuscular, intravenous, liposome mediated delivery, topical, nasal, oral, anal, ocular or otic delivery.
62. (Previously Presented) The method of claim 42, wherein the method is for preventing a disease involving β -sheet fibril formation.

63. (Previously Presented) The method of claim 42, wherein the method is for treating a disease involving β -sheet fibril formation.
64. (Previously Presented) The method of claim 42, wherein the disease is diabetes.
65. (Previously Presented) The method of claim 42, wherein the disease is hyperlipidemic atherosclerosis.
66. (Previously Presented) The method of claim 42, wherein the disease is neuropathy.
67. (Previously Presented) The method of claim 42, wherein the disease is nephropathy.
68. (Previously Presented) The method of claim 42, wherein the disease is amyloidosis.
69. (Previously Presented) The method of claim 42, wherein the disease is a wound associated with diabetes.
70. (Previously Presented) The method of claim 42, wherein the β -sheet fibril comprises a peptide capable of forming amyloid.